Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer

The April 1997 article entitled, "Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer" by Ahlert et al (J Clin Oncol 15:1354–1366, 1997) contained several errors. On page 1354, the affiliation should have read: from the Universitat-Frauenklinik Heidelberg; Deutsches Krebsforschungszentrum Heidelberg, Abteilung 710; Forschungspraxis Technologiepark Heidelburg; Institute fur medizinische Biometrie und Informatik, Universitat Freiburg, Freiburg, Germany. Reference number 36 on page 1365 should have read: 36. Pomer S, Schirrmacher V, Thiele R, et al: Tumor response and 4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-alpha 2b. Int J Oncol 6:941–954, 1995 In addition, Table 5 is reprinted here correctly in its entirety: Please see the PDF for table 5.